Markets:

Overview

News

Currencies

International

Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.435 -0.125 (-2.74%)

Delayed Quote Updated: 11:57 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 Next >

There are notable gap-ups and gap-downs in today's session. ↗

August 21, 2026

Via Chartmill

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗

March 04, 2026

The news is likely to come as a relief to many investors, Citi told investors in a research note.

Via Stocktwits

Topics Intellectual Property

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗

January 16, 2026

Via Stocktwits

Topics Intellectual Property

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance ↗

May 04, 2023

Via Benzinga

Recap: Arbutus Biopharma Q1 Earnings ↗

May 04, 2023

Via Benzinga

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗

March 03, 2026

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Via Stocktwits

Topics Intellectual Property

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Topics Initial Public Offering Intellectual Property Lawsuit

Get insights into the top gainers and losers of Friday's pre-market session. ↗

January 16, 2026

Via Chartmill

Arbutus Biopharma's Earnings Outlook ↗

May 03, 2023

Via Benzinga

Why Arbutus Biopharma Stock Is Sinking Today ↗

April 25, 2023

After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.

Via The Motley Fool

Why Arbutus Biopharma Stock Is Plunging Today ↗

April 25, 2023

Via Benzinga

Arbutus Biopharma's Return On Capital Employed Insights ↗

December 12, 2022

Via Benzinga

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗

October 21, 2025

Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains.

Via Chartmill

Arbutus (ABUS) Q2 Revenue Surges 529% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 20, 2024

Via Benzinga

Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗

October 03, 2024

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible...

Via Benzinga

Topics Intellectual Property

Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts ↗

August 01, 2024

While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.

Via InvestorPlace

Topics Workforce

ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 ↗

May 02, 2024

ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble ↗

April 05, 2024

The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood.

Via InvestorPlace

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge ↗

April 04, 2024

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

Via Benzinga

Topics Intellectual Property

Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead ↗

April 04, 2024

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.

Via Benzinga

Topics Intellectual Property

Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim ↗

April 03, 2024

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.

Via Benzinga

Topics Intellectual Property

Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute ↗

October 05, 2023

Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin

Via Benzinga

Topics Intellectual Property Lawsuit

US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma ↗

April 12, 2023

Via Benzinga

Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗

April 04, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.